Cargando…

Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis

SIMPLE SUMMARY: Prostate cancer (PCa) represents the most common male urologic neoplasia. In the present study, the authors performed a review of scientific literature to establish the most potentially valuable biomarkers. After this a meta-analysis of two most interesting biomarkers (BRCA 1 and 2 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Domrazek, Kinga, Pawłowski, Karol, Jurka, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340691/
https://www.ncbi.nlm.nih.gov/pubmed/37444562
http://dx.doi.org/10.3390/cancers15133452
_version_ 1785072139996495872
author Domrazek, Kinga
Pawłowski, Karol
Jurka, Piotr
author_facet Domrazek, Kinga
Pawłowski, Karol
Jurka, Piotr
author_sort Domrazek, Kinga
collection PubMed
description SIMPLE SUMMARY: Prostate cancer (PCa) represents the most common male urologic neoplasia. In the present study, the authors performed a review of scientific literature to establish the most potentially valuable biomarkers. After this a meta-analysis of two most interesting biomarkers (BRCA 1 and 2 and ctDNA) has been performed to evaluate their utility for the diagnostics, treatment, and prognosis of prostate cancer. The obtained results can help select the best diagnostic tool for early prostate diagnosis. To date, no ideal PCa biomarker has been found. Although BRCA1 and BRCA2 work well for breast and ovarian cancers, they do not seem to be reliable for prostate cancer. In our opinion, ctDNA seems to be a very promising biomarker, but still more research in this field is needed. ABSTRACT: Prostate cancer represents the most common male urologic neoplasia. Tissue biopsies are the gold standard in oncology for diagnosing prostate cancer. We conducted a study to find the most reliable and noninvasive diagnostic tool. We performed a systematic review and meta-analysis of two biomarkers which we believe are the most interesting: BRCA (BRCA1 and 2) and ctDNA. Our systematic research yielded 248 articles. Forty-five duplicates were first excluded and, upon further examination, a further 203 articles were excluded on the basis of the inclusion and exclusion criteria, leaving 25 articles. A statistical analysis of the obtained data has been performed. With a collective calculation, BRCA1 was expressed in 2.74% of all cases from 24,212 patients examined and BRCA2 in 1.96% of cases from 20,480 patients. In a total calculation using ctDNA, it was observed that 89% of cases from 1198 patients exhibited high expression of circulating tumor DNA. To date, no ideal PCa biomarker has been found. Although BRCA1 and BRCA2 work well for breast and ovarian cancers, they do not seem to be reliable for prostate cancer. ctDNA seems to be a much better biomarker; however, there are few studies in this area. Further studies need to be performed.
format Online
Article
Text
id pubmed-10340691
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103406912023-07-14 Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis Domrazek, Kinga Pawłowski, Karol Jurka, Piotr Cancers (Basel) Article SIMPLE SUMMARY: Prostate cancer (PCa) represents the most common male urologic neoplasia. In the present study, the authors performed a review of scientific literature to establish the most potentially valuable biomarkers. After this a meta-analysis of two most interesting biomarkers (BRCA 1 and 2 and ctDNA) has been performed to evaluate their utility for the diagnostics, treatment, and prognosis of prostate cancer. The obtained results can help select the best diagnostic tool for early prostate diagnosis. To date, no ideal PCa biomarker has been found. Although BRCA1 and BRCA2 work well for breast and ovarian cancers, they do not seem to be reliable for prostate cancer. In our opinion, ctDNA seems to be a very promising biomarker, but still more research in this field is needed. ABSTRACT: Prostate cancer represents the most common male urologic neoplasia. Tissue biopsies are the gold standard in oncology for diagnosing prostate cancer. We conducted a study to find the most reliable and noninvasive diagnostic tool. We performed a systematic review and meta-analysis of two biomarkers which we believe are the most interesting: BRCA (BRCA1 and 2) and ctDNA. Our systematic research yielded 248 articles. Forty-five duplicates were first excluded and, upon further examination, a further 203 articles were excluded on the basis of the inclusion and exclusion criteria, leaving 25 articles. A statistical analysis of the obtained data has been performed. With a collective calculation, BRCA1 was expressed in 2.74% of all cases from 24,212 patients examined and BRCA2 in 1.96% of cases from 20,480 patients. In a total calculation using ctDNA, it was observed that 89% of cases from 1198 patients exhibited high expression of circulating tumor DNA. To date, no ideal PCa biomarker has been found. Although BRCA1 and BRCA2 work well for breast and ovarian cancers, they do not seem to be reliable for prostate cancer. ctDNA seems to be a much better biomarker; however, there are few studies in this area. Further studies need to be performed. MDPI 2023-06-30 /pmc/articles/PMC10340691/ /pubmed/37444562 http://dx.doi.org/10.3390/cancers15133452 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Domrazek, Kinga
Pawłowski, Karol
Jurka, Piotr
Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
title Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
title_full Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
title_fullStr Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
title_full_unstemmed Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
title_short Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
title_sort usefulness of brca and ctdna as prostate cancer biomarkers: a meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340691/
https://www.ncbi.nlm.nih.gov/pubmed/37444562
http://dx.doi.org/10.3390/cancers15133452
work_keys_str_mv AT domrazekkinga usefulnessofbrcaandctdnaasprostatecancerbiomarkersametaanalysis
AT pawłowskikarol usefulnessofbrcaandctdnaasprostatecancerbiomarkersametaanalysis
AT jurkapiotr usefulnessofbrcaandctdnaasprostatecancerbiomarkersametaanalysis